Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1998-12-17
|
| pubmed:abstractText |
While abundant data exist documenting variables associated with early platelet engraftment after autologous PBPC transplantation, data concerning later sustained platelet engraftment is sparse. We retrospectively examined a series of 80 patients undergoing autologous PBPC transplantation with respect to their platelet count 6 weeks after transplant. Underlying diagnoses included breast cancer (n = 33), non-Hodgkin's lymphoma (n = 32), Hodgkin's disease (n = 9), and other hematologic malignancies (n = 6). Patients received G-CSF for PBPC mobilization and collected a target threshold number of 2.0 x 10(6) CD34+ cells per kilogram. A univariate analysis revealed that a diagnosis of breast cancer, fewer courses of prior chemotherapy, younger age and complete remission were associated with a higher 6-week platelet count. Additionally, the ability to collect the threshold number of CD34+ with fewer sessions of leukapheresis was also associated with a higher 6-week platelet count. The platelet count and the white blood cell count at the initiation of PBPC collection was also associated with a higher 6-week platelet count. A multivariate analysis revealed a higher platelet count on the first day of pheresis, fewer phereses required to collect 2 x 10(6) CD34+ cells per kilogram, and a diagnosis of breast cancer were all associated with a higher 6-week post-transplant platelet count. Seven patients failed to reach a 6-week platelet count of 30 x 10(9)/l and an additional five patients had a platelet count of 30-50 x 10(9)/l. We conclude that underlying clinical characteristics, as well as hematologic variables at the time of PBPC collection, influence later, sustained platelet engraftment. A percentage of patients have poor sustained platelet engraftment and may be candidates for new cytokines that specifically target megakaryocyte growth and development.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
22
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
547-51
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9758341-Adult,
pubmed-meshheading:9758341-Antigens, CD34,
pubmed-meshheading:9758341-Breast Neoplasms,
pubmed-meshheading:9758341-Female,
pubmed-meshheading:9758341-Graft Survival,
pubmed-meshheading:9758341-Hematologic Neoplasms,
pubmed-meshheading:9758341-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9758341-Hematopoietic Stem Cells,
pubmed-meshheading:9758341-Hodgkin Disease,
pubmed-meshheading:9758341-Humans,
pubmed-meshheading:9758341-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9758341-Male,
pubmed-meshheading:9758341-Middle Aged,
pubmed-meshheading:9758341-Platelet Count,
pubmed-meshheading:9758341-Prognosis,
pubmed-meshheading:9758341-Retrospective Studies,
pubmed-meshheading:9758341-Time Factors,
pubmed-meshheading:9758341-Transplantation, Autologous
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation.
|
| pubmed:affiliation |
Department of Hematology and Medical Oncology, and Transplant Center, The Cleveland Clinic Foundation, OH 44195, USA.
|
| pubmed:publicationType |
Journal Article
|